Immuron Board Changes

Core Viewpoint - Immuron Limited announces the resignation of Dr. Roger Aston as Non-Executive Director and the appointment of Dr. Jeannie Joughin, highlighting ongoing positive changes and strategic advancements within the company [1][4][5]. Company Developments - Immuron has experienced significant positive changes, accelerating commercial activities through enhanced marketing and strategic intent [2]. - The company is focusing on long-term improvements in manufacturing and supply chain to meet anticipated demand over the next decade [3]. - Immuron's partnership with the US Military is yielding strong evidence for preventative strategies against infectious diseases [3]. Leadership Changes - Dr. Roger Aston has resigned due to family commitments in the UK after 12 years of service, contributing significantly to the company's direction and capital raising during challenging periods [4]. - Dr. Jeannie Joughin has been appointed as a Non-Executive Director, bringing extensive experience from her roles in major pharmaceutical companies, which will support Immuron's clinical and commercial programs [5]. Product Focus - Immuron's proprietary technology involves developing orally delivered targeted polyclonal antibodies for treating infectious diseases, particularly through its product Travelan®, which helps prevent traveler's diarrhea [6][7][10]. - The company is advancing its research on Clostridium difficile preventive and curative products, showing great potential for future development [3].